Travere (TVTX) CFO Christopher Cline Sells 642 Shares

What Happened

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics (TVTX), disposed of 642 shares on 2026-09-02 at $66.37 per share, generating gross proceeds of $42,610. This was a sale (S) executed as a broker "sell-to-cover" to satisfy tax withholding tied to the settlement of vested restricted stock units, not a discretionary open-market trade.

Key Details

• Transaction date: 2026-09-02; filing date: 2026-09-03 (timely).
• Price per share: $66.37; shares sold: 642; total proceeds: $42,610.
• Shares owned after transaction: not reported in the information provided.
• Footnote: Sale mandated to cover tax withholding for vested RSUs (sell-to-cover via issuer‑designated broker); not a voluntary trade by the insider (see F1).
• Transaction code: S = Sale; related footnote code indicates tax-withholding (F).

Context

• Sell-to-cover transactions are routine administrative actions to satisfy tax obligations when restricted stock units vest and generally do not reflect an insider’s discretionary view on the company’s shares. This filing reports the mandatory withholding sale; it is factual and should not be interpreted as a deliberate directional trade.